Novel Therapies for Type 2 Diabetes: Incretin-Based and Glucosuric Therapies

Silvio E. Inzucchi, MD
Professor of Medicine
Clinical Chief, Endocrinology
Medical Director, Yale Diabetes Center
Program Director, Endocrinology & Metabolism Fellowship
Yale School of Medicine

May 7, 2020 • 4:00-5:00 pm
Dial-In: 203.432.9666; Meeting ID: 201.194.039; https://zoom.us/j/201194039

There is no corporate support for this activity.

Course Director/Host: Lubna Pal, MBBS, FRCOG, MS, FACOG

ACCREDITATION:
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE:
ObGyn attending physicians, house staff/fellows, medical students, nurses, PA’s, community Ob/Gyn’s, residents, midwives, nurses and researchers.

NEEDS ASSESSMENT:
There is growing complexity to the management of Type 2 diabetes, owing to an increasing array of glucose lowering agents available and a rapidly evolving treatment landscape. OB-GYN physicians frequently evaluate women who have diabetes and would benefit from an update on two newer classes of diabetes medications, the GLP-1 receptor agonists and the SGLT2 inhibitors.

LEARNING OBJECTIVES:
At the end of this presentation, attendees will be able to:
1. Review the pathogenesis of Type 2 diabetes;
2. List the oral and injectable agents used to lower glucose in patients with Type 2 diabetes; and
3. Focus on new data re SGLT2 inhibitors and GLP-1 receptor agonists.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES:
Course Director: Lubna Pal, MD
Flo Health, Consultant
AMAG Advisory Board, Member
GLG, Consultant
Abbott Advisory Board, Member

Speaker: Silvio E. Inzucchi, MD
Grant/Research: NIDDK
Consultant: Merck, Astra Zeneca, Novo Nordisk, vTV Therapeutics,
Abbott/Alere
Research Steering/Executive/Publications Committees: Boehringer-Ingelheim, Astra Zeneca, Novo Nordisk, Sanofi/Lexinon

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.